Considerations When Treating Patients With Metastatic Renal Cell Carcinoma
Similar to first-line therapy choices, particular treatment factors, including type
and duration of response to prior therapy, pace of disease progression, and toxicities associated with first-line treatment, are all practical considerations that help guide therapy selection in metastatic renal cell carcinoma.
Dr. Aragon-Ching on the Use of Maintenance Avelumab in Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, discusses the use of maintenance avelumab as the standard-of-care treatment for patients with locally advanced or metastatic urothelial carcinoma.
Key Trial Data in Urothelial Carcinoma Treatment from ESMO 2022
Srikala Sridhar, MD, MSc, FRCPC, and Jeanny B. Aragon-Ching, MD, FACP, wrap up their review of updates in urothelial carcinoma by highlighting exciting data presented at ESMO 2022.
Metastatic Urothelial Carcinoma Treatment after Disease Progression on Avelumab
Key opinion leaders discuss the best treatment approaches for urothelial carcinoma after avelumab failure.
Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer
Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.
Outcomes of the JAVELIN Bladder 100 Trial
Jeanny B. Aragon-Ching, MD, FACP, describes the outcomes of the JAVELIN Bladder 100 study that she presented at ESMO 2022.
Treatment Options for Frontline Metastatic Urothelial Carcinoma
Drs Aragon-Ching and Sridhar review the available treatment options for patients with frontline metastatic urothelial carcinoma and explain the design of an exciting clinical trial.
Neoadjuvant Chemotherapy in Urothelial Carcinoma: The IMvigor010 Study
Dr Jeanny B. Aragon-Ching starts a conversation on negative trial data in the high-risk urothelial carcinoma treatment setting for neoadjuvant chemotherapy.
Neoadjuvant Chemotherapy in Urothelial Carcinoma: The CHECKMATE-274 Trial
Experts discuss trial data from CHECKMATE-274 on the use of neoadjuvant chemotherapy for high-risk urothelial carcinoma treatment.
Neoadjuvant Chemotherapy as Standard-of-Care for Muscle-Invasive Urothelial Carcinoma
Srikala Sridhar, MD, MSc, FRCPC, explains the importance of neoadjuvant cisplatin-based chemotherapy and why bladder-sparing treatments should be considered for all patient populations.
Incidence and Risk Factors for Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, provides an overview of urothelial cancers and the process of diagnosis.
Dr. Aragon-Ching on the Evolving Standard of Care with JAVELIN Bladder 100 in Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, discusses the evolving standard of care based on findings from the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.
Dr. Aragon-Ching on the Implications of the JAVELIN Bladder 100 Trial in Urothelial Carcinoma
Jeanny B. Aragon-Ching, MD, FACP, discusses the clinical implications of the phase 3 JAVELIN Bladder 100 trial in urothelial carcinoma.
PD-1 Inhibitor Combinations, Alternative Therapeutic Approaches Are Moving the Needle in NSCLC
Better Understanding of Biomarkers Can Inform Immunotherapy Treatment in SCLC
Second-Line Treatment of R/R LBCL With Lisocabtagene Maraleucel (Liso-cel)
ZUMA-7: Axicabtagene Ciloleucel as a Second-Line Therapy for LBCL
2 Clarke Drive Cranbury, NJ 08512